
































Arthroplasty Versus Internal Fixation for the Treatment of
Undisplaced Femoral Neck Fractures: A Retrospective
Cohort Study
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and Gerard P. Slobogean, MD, MPHa on behalf of the FAITH and HEALTH Investigators
Objective: To compare the 24-month risk of mortality between
arthroplasty and internal fixation for undisplaced femoral neck
fractures (FNFs).
Design: Retrospective cohort study.
Setting: Secondary data analysis of 2 multinational randomized
controlled trials.
Participants: Patients aged 50 years or older with a FNF.
Intervention: Arthroplasty (n = 1441), including total hip arthro-
plasty and hemiarthroplasty, performed for a displaced FNF versus
internal fixation (n = 734), including sliding hip screw or multiple
cancellous screws, performed for an undisplaced FNF.
Main Outcome Measurement: The primary outcome was
mortality within 24 months of injury. Secondary outcomes included
reoperation and health-related quality of life.
Results: The 24-month mortality rate was 15.0% (n = 327).
Arthroplasty was associated with a significant reduction in the odds
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of mortality [adjusted odds ratio (aOR): 0.56, 95% confidence
interval (CI): 0.44–0.72, P , 0.01] compared with treatment with
internal fixation. 11.4% (n = 248) of the study patients required
reoperation within 24 months of injury. The odds of reoperation
were 59% lower with arthroplasty treatment than with internal
fixation (aOR: 0.41, 95% CI: 0.32–0.55, P , 0.01). The 24-
month SF-12 physical component scores were 2.7 points higher
in arthroplasty patients compared with internal fixation patients
(95% CI: 1.6–3.8, P , 0.01).
Conclusions: Our findings suggest arthroplasty for a FNF may
reduce the risk of mortality and reoperation compared with internal
fixation of undisplaced fractures. This finding is counter to many
current surgical practices but consistent with a mounting body of
evidence. Before widespread adoption of arthroplasty for undis-
placed fractures, these results should be confirmed in a definitive
comparative trial.
Key Words: arthroplasty, internal fixation, undisplaced femoral
neck fracture
Level of Evidence: Therapeutic Level III. See Instructions for
Authors for a complete description of levels of evidence.
(J Orthop Trauma 2020;34:S9–S14)
BACKGROUND
Two decades ago, the optimal treatment of displaced
femoral neck fractures (FNFs) was controversial.1 A
mounting body of evidence has since shifted clinical prac-
tice in favor of arthroplasty for displaced FNF manage-
ment.2,3 However, for undisplaced FNFs, internal fixation
remains the preferred approach as a less invasive procedure
with less expensive implants. A recent randomized trial
comparing hemiarthroplasty with internal fixation in non-
displaced FNFs contested the current practice,4 suggesting
improved mobility and fewer major reoperations with hem-
iarthroplasty. This finding was consistent with another
small trial and 2 recent retrospective cohort studies in min-
imally displaced FNF patients.5–7
Given the limited comparative data for the optimal
treatment of undisplaced FNFs, we aimed to determine if
arthroplasty in patients aged 50 years or older with displaced
FNFs was associated with reduced mortality, fewer reoperations,
and higher health-related quality of life compared with internal
fixation for undisplaced FNFs in patients aged 50 years or older.
We hypothesized that arthroplasty would decrease mortality,
reduce reoperations, and increase health-related quality of life
scores.8 We also assessed the variation in treatment effect across
various prefracture risk profiles. We hypothesized that the ben-
efits of arthroplasty treatment would be greater in high-risk FNF
patients.
METHODS
Study Design and Procedures
This retrospective cohort study combined data from the
HEALTH and FAITH clinical trials.9,10 The HEALTH trial
was an international, expertise-based clinical trial conducted
between 2013 and 2016 that enrolled 1495 participants from
80 centers. HEALTH participants were randomized to either
total hip arthroplasty or hemiarthroplasty to treat a displaced
FNF. The FAITH trial was also an international multicenter
randomized clinical trial performed at 81 centers from 2008
through 2014. In FAITH, 1108 participants were randomized
to either multiple cancellous screws or sliding hip screw fix-
ation for the treatment of a low-energy FNF. Both trials were
coordinated by McMaster University and were approved by
the Ethics Committee at McMaster University and all partici-
pating centers.
Eligibility Criteria
We included participants aged 50 years or older with a
low-energy fracture of the femoral neck. Eligible participants
must have been able to ambulate either without assistance or
assistance from an aid before the injury. Patients with rheuma-
toid arthritis, pathological fractures or severe osteoarthritis of the
hip, other major injuries of the lower extremities, retained
implant around the affected hip, infection around the hip,
disorder of bone metabolism, and previous history of dementia
were excluded. The FAITH trial included all FNFs amenable to
surgical fixation but primarily included minimally displaced
fractures, whereas HEALTH only included displaced fractures
being treated with arthroplasty. All fractures were classified by
each trial’s Central Adjudication Committee using the Garden
classification, and Garden I and II fractures were considered
undisplaced.11,12
Because the target population for this study was
undisplaced fractures, we excluded the displaced fracture
patients from the FAITH trial. However, we included all
patients from the HEALTH trial because the degree of
fracture displacement has no effect on healing since the
femoral head and neck is resected and should have no
impact on the outcome after the arthroplasty procedure.
Study Treatments
Participants in the arthroplasty treatment group received
either total hip arthroplasty or hemiarthroplasty as per the
randomized allocation within the HEALTH trial. Treating
surgeons had to meet a predefined threshold for surgical
expertise in the procedures. Similarly, the internal fixation
group comprised patients that were randomly assigned a
sliding hip screw or multiple cancellous screws. The sliding
hip screw was a single large-diameter, partly threaded screw
affixed to the proximal femur with a side plate. Treatment
with cancellous screws required a minimum of 2 threaded
screws with a 6.5-mm diameter. Surgeons treating partici-
pants with internal fixation were required to have performed
at least 25 hip fracture fixation procedures in their career,
including at least 5 procedures in the year before the study
treatment.
Study Outcomes
The primary end point was mortality within 24 months of
injury. The secondary outcomes included reoperation within 24
months and health-related quality of life. Reoperation was
defined as any operation subsequent to the initial procedure to
promote fracture healing, relieve pain, treat infection, or improve
function. Health-related quality of life was measured with the
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12-item Short-Form General Health Survey (SF-12), which
reports physical component summary (PCS) and mental com-
ponent summary (MCS) scores on a scale of 0–100.13 SF-12
scores were normalized to a population mean of 50, with higher
scores implying greater health.
Statistical Analysis
Patient characteristics were described using counts with
proportions and means with SDs, depending on the distribution
of the data. Categorial data were compared between the
treatment arms using x2 tests. Continuous variables were com-
pared using t tests. To measure for potential confounding, we
assessed for the distribution of covariates between the 2 surgi-
cal exposure groups and outcomes. If the covariates differed
significantly between the exposure and outcome or resulted in a
change in the effect measure of 10% or greater when added to
the unadjusted model, they were included in the final adjusted
analysis. Logistic regression models were used to determine
the association of treatment with mortality and reoperation. All
covariates listed under Table 1 were assessed for potential
confounding. Using the above criteria, the final adjusted model
for mortality included age and the American Society of
Anesthesiologists (ASA) classification. ASA classification
was the only confounder included in the reoperation model.
The association between treatment and 24-month health-related
quality of life scores was estimated using linear regression.
Estimates for physical health quality of life included ASA
classification, additional injuries, and preinjury back pain as
confounders. Mental health quality of life estimates were con-
ditioned on sex and preinjury depression as confounders.
To assess variations in the treatment effect on mortality
across risk strata, we used the risk modeling approach
described by Kent et al.14 Briefly, we developed a risk pre-
diction model for mortality omitting the treatment variable.
The data-informed risk model included age, sex, ASA classi-
fication, prefracture functional status, cancer, and anemia or
other blood diseases with a C-statistic of 0.76. Based on the
risk model, the probability of mortality was assigned to each
patient. We then binned the study sample into risk quartiles
based on the probability of death. In each risk quartile, we
calculated the association between treatment and mortality on
a relative (odds ratio) and absolute scale (risk difference).
Statistical analyses were performed using SAS 9.4 (SAS
Institute, Cary, NC) and R version 4.0.0 (Vienna, Austria).
Missing covariate data were imputed using multiple imputations.15
RESULTS
Of the 2175 patients included in the study, 1441 were
treated with arthroplasty, and 734 were treated with internal
TABLE 1. Patient Characteristics
Characteristic Arthroplasty (n = 1441) Internal Fixation (n = 734) P
Age, y, mean (SD) 78.8 (8.4) 74.2 (11.9) ,0.01
Female, n (%) 1009 (70.1%) 488 (66.5%) 0.09
BMI, kg/m2, mean (SD) 25.1 (4.8) 24.3 (4.5) ,0.01
Mechanism of injury, n (%) ,0.01
Fall from standing 1396 (97.2%) 711 (97.3%)
Spontaneous fractures 30 (2.1%) 15 (2.1%)
Fall from small height 11 (0.8%) 0 (0.0%)
Others 0 (0.0%) 5 (0.7%)
ASA classification, n (%) ,0.01
Class I–II 652 (45.3%) 414 (56.4%)
Class III–IV 789 (54.8%) 320 (43.6%)
Prefracture functional status, n (%) 0.95
Independent ambulator 1072 (74.4%) 547 (74.5%)
Use of aid 369 (25.6%) 187 (25.5%)
Prefracture living status, n (%) 0.22
Institutionalized 65 (4.5%) 42 (5.7%)
Not institutionalized 1376 (95.5%) 692 (94.3%)
Additional injuries, n (%) 61 (4.3%) 110 (15.0%) ,0.01
Hypertension, n (%) 877 (61.0%) 412 (56.4%) 0.04
Diabetes, n (%) 280 (19.5%) 116 (15.9%) 0.04
Back pain, n (%) 135 (9.4%) 163 (22.4%) ,0.01
Cancer, n (%) 145 (10.1%) 102 (14.0%) ,0.01
Anemia or other blood diseases,
n (%)
103 (7.2%) 82 (11.3%) ,0.01
Ulcer, n (%) 116 (8.1%) 119 (16.3%) ,0.01
Depression, n (%) 154 (10.7%) 130 (17.8%) ,0.01
ASA, American Society of Anesthesiologists; BMI, body mass index.
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fixation (Table 1). Patients in the arthroplasty group were
older (78.8 vs. 74.2 years, P , 0.01) and more likely to have
an ASA classification of 3–5 (54.8% vs. 43.6%, P , 0.01).
We did not observe a significant difference in the proportion
of patients requiring an aid before injury (25.6% vs. 25.5%, P
= 0.95) or institutionalized before the fracture (4.5% vs. 5.7%,
P = 0.22). The 24-month mortality rate was 15.0% (n = 327).
Treatment with arthroplasty significantly reduced the odds of
mortality [adjusted odds ratio (aOR): 0.56, 95% CI: 0.44–
0.72, P , 0.01] compared with treatment with internal fixa-
tion (Table 2). 11.4% (n = 248) of the study patients required
reoperation within 24 months of injury. The odds of reopera-
tion were 59% lower with arthroplasty treatment than those
with treatment by internal fixation (aOR: 0.41, 95% CI: 0.32–
0.55, P , 0.01). The 24-month SF-12 physical component
scores were 2.7 points higher in arthroplasty patients than
those of internal fixation patients (95% CI: 1.6–3.8, P ,
0.01). No difference in 24-month SF-12 mental component
scores was observed between the 2 treatment groups (adjusted
difference: 0.9, 95% CI: 20.3—2.0, P = 0.14).
The characteristics of the patients based on their
mortality risk quartile are available in Table 3. The mean risk
of mortality was 3.7% in the lowest risk quartile, 7.4% in the
low-mid risk quartile, 16.0% in the mid-high risk quartile, and
33.1% in the high-risk quartile (Fig. 1). The point estimates
for ORs and risk differences favored arthroplasty across the 4
risk quartiles. However, only significant differences were
observed in the highest risk quartile with an OR of 0.54
[95% confidence interval (CI): 0.37–0.78] and a risk reduc-
tion of 14.1% (95% CI: 5.7%–22.6%).
DISCUSSION
The findings of our study suggest that arthroplasty
reduced the risk of mortality and reoperation within 24
months after injury compared with internal fixation in
undisplaced FNFs. Arthroplasty was also associated with a
mild, yet statistically significant, improvement in overall
physical health. The study treatment was not associated with
a difference in overall mental health. We observed that
arthroplasty provided the strongest protective effects against
mortality in our high-risk strata patients.
Previous studies have suggested that arthroplasty is
associated with lower reoperations when compared with
internal fixation of minimally displaced fractures.4–8
Consistent with the 2 previous trials and 2 previous observa-
tional analyses in this population,4–7 we observed a similar
magnitude of reduced odds of reoperation associated with
arthroplasty. However, the survival benefits observed in our
study contradict the 2 previous observational studies,5,6 which
suggested internal fixation was protective against mortality. In
these studies, the effects of selection bias cannot be deter-
mined, and therefore, it is important to note that the prospec-
tive randomized trial comparing the arthroplasty and internal
fixation treatments for mortality is consistent with our study
results.4 In the trial by Dolatowski et al,4 mortality was
TABLE 2. Study Outcomes
Arthroplasty (n = 1441) Internal Fixation (n = 734) Crude OR (95% CI) P Adjusted OR (95% CI) P
Mortality, n (%) 198 (13.7%) 129 (17.6%) 0.75 (0.59–0.95) 0.02 0.56 (0.44–0.73) ,0.01






(95% CI) P Adjusted Difference (95% CI) P
24-mo SF-12 PCS, mean (SD) 38.8 (9.9) 36.1 (9.9) 2.7 (1.7–3.8) ,0.01 2.7 (1.6–3.8) ,0.01
24-mo SF-12 MCS, mean (SD) 52.3 (10.6) 51.2 (14.5) 1.1 (20.1–2.3) 0.07 0.9 (20.3–2.0) 0.14
Only a subset of arthroplasty and internal fixation patients were administered the SF-12 survey as per the study protocols.
PCS, physical component summary; MCS, mental component summary.
TABLE 3. Characteristic of Mortality Risk Quartiles
Low Risk (1) (N = 544) Low-Mid Risk (2) (N = 544) Mid-High Risk (3) (N = 544) High Risk (4) (N = 543)
Age, yrs, mean (SD) 67.2 (8.9) 77.1 (7.8) 80.9 (7.3) 83.8 (7.0)
Female, n (%) 449 (82.5%) 382 (70.2%) 362 (66.5%) 305 (56.2%)
ASA classification, n (%)
Class I–II 505 (92.8%) 345 (63.4%) 177 (32.5%) 39 (7.2%)
Class III–IV 39 (7.2%) 199 (36.6%) 367 (67.5%) 504 (92.8%)
Prefracture functional status, n (%)
Independent ambulator 538 (98.9%) 522 (96.0%) 407 (74.8%) 152 (28.0%)
Use of aid 6 (1.1%) 22 (4.0%) 137 (25.2%) 391 (72.0%)
Anemia or other blood diseases,
n (%)
1 (0.2%) 11 (2.0%) 37 (6.8%) 137 (25.2%)
Cancer, n (%) 9 (1.7%) 32 (5.9%) 62 (11.4%) 146 (26.9%)
ASA, American Society of Anesthesiologists.
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reported as a secondary outcome, and although the benefits of
hemiarthroplasty were not statistically significant in their
study (P = 0.11), the point estimate suggested a 60% relative
risk reduction. Similarly, consistent with our SF-12 PCS
results, the trial by Dolatowski et al observed a 10% benefit
in health-related quality of life with hemiarthroplasty com-
pared with internal fixation.4
There are several possible mechanisms for the observed
benefits of arthroplasty in this patient population. Despite the
more invasive procedure, a hip arthroplasty immediately
creates a stable weight-bearing construct. This may contribute
to less pain and earlier clinically significant mobilization,
particularly because delayed mobilization has been previously
demonstrated to lead to reduced function and lower survival
in hip fracture patients.16 Similarly, arthroplasty is associated
with less reoperations than internal fixation, and this likely
contributes to reduced mortality and improved clinical out-
comes. In our study, this reduction in mortality was observed
despite HEALTH participants remaining at a greater risk for
mortality. These risk factors included older age and higher
ASA prevalence. Therefore, although both clinical trials may
have recruitment biases, such as HEALTH potentially recruit-
ing a healthier population of displaced FNF patients suitable
for randomization to total hip arthroplasty, the benefits of
arthroplasty seem to still outweigh the difference in mortality
risk factors.
To better understand potential participant recruitment
biases between the trials and the substantial variation in risk
of mortality in the pooled study population, we used a novel
risk modeling approach to assess the heterogeneity of
treatment effect (HTE).14 HTE describes variation in the
magnitude of treatment effect based on clinically relevant
patient attributes (subgroups).17 The risk modeling tech-
nique allowed us to account for an imbalance in baseline
covariates between the treatment groups, assess the prognos-
tic value of the observed variables, and estimate differences
in treatment effects across clinically unique strata. Although
all HTE treatment estimates favored arthroplasty, the most
substantial mortality benefits were observed in the oldest,
sickest patients.
With more than 2000 patients, our study is 3 times
larger than the 4 previous studies combined.4–7 We used data
from 2 recent, high-quality, multinational, randomized tri-
als.9,10 The risk modeling technique for analyzing HTE rep-
resents an improvement over classic subgroup analysis, which
is prone to low statistical power, multiplicity, and weak pre-
vious theory on relative effect modifiers and, therefore, sus-
ceptible to false-negative and false-positive findings. As
patients have many attributes that simultaneously affect the
study outcome, modeling their combined effects produced a
more patient centered and clinically actionable estimate of
treatment effects.
Despite the strengths of the study, there were some
limitations. With regards to osteoporosis or smoking status,
an important prognostic factor for both mortality and failure,
only HEALTH had data for osteoporosis, whereas smoking
status was collected only under FAITH. For this reason, we
were unable to include these variables in our analysis.
Furthermore, although the treatment decision for internal
FIGURE 1. Association between treatment and mortality by
risk quartile. The figure presented the mean risk of mortality
with ranges by risk quartile (top), and the association between
treatment and mortality by quartile based on observed odds
ratios (middle) and risk differences (bottom).
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fixation has traditionally been based on fracture displacement
defined within the Garden classification (type I and II), more
recent studies have highlighted the importance of also
assessing the fracture alignment on the lateral hip radiograph.
In certain fractures that seem minimally displaced on ante-
roposterior radiographs, large amounts of posterior angulation
on the lateral view are highly predictive of internal fixation
failure.18 These previous findings suggest another layer of
treatment decision complexity that favors widespread adop-
tion of arthroplasty in this patient population.
Currently, the conventional treatment for an undis-
placed or minimally displaced FNF is internal fixation.
Arthroplasty has been typically disregarded in this fracture
population given the invasive nature of the procedure, the cost
of the implant, and the presumed good clinical results from
internal fixation. As newer data continue to emerge, it
becomes apparent that the results of internal fixation for
undisplaced fractures are often poor and that hip arthroplasty
reduces reoperations and potentially reduces mortality. Our
results continue to challenge the prevailing practice of
internal fixation for these fractures; however, definitive
evidence from a large, appropriately powered trial remains
warranted before a widespread practice change.
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